Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -38.32% is 16% above its 5-year average of -45.63%, near the high end of its 5-year range (-162.78%–-19.49%).
As of the fiscal period ended Tuesday, June 30, 2026. 25.68% below its 12-month average of -30.49%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -38.32%.
RETURN ON EQUITY (ROE)
-38.32%
RETURN ON EQUITY (ROE) AVG TTM
-30.49%
RETURN ON EQUITY (ROE) AVG 3Y
-34.69%
RETURN ON EQUITY (ROE) AVG 5Y
-45.63%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-25.68%
CURRENT VS 3Y AVG
-10.47%
CURRENT VS 5Y AVG
+16.01%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+8.77%
vs the sector median at left
Tectonic Therapeutic, Inc.
Market Cap
$436.92M
Return on Equity (ROE)
-38.32%
TTM Avg
-30.49%
3Y Avg
-34.69%
5Y Avg
-45.63%
Market Cap
$438.56M
Return on Equity (ROE)
-0.01%
TTM Avg
-61.70%
3Y Avg
-96.25%
5Y Avg
-81.28%
Market Cap
$442.54M
Return on Equity (ROE)
-52.56%
TTM Avg
-31.09%
3Y Avg
-101.75%
5Y Avg
-86.54%
Market Cap
$430.46M
Return on Equity (ROE)
-70.24%
TTM Avg
-381.56%
3Y Avg
-217.03%
5Y Avg
-155.40%
Market Cap
$429.36M
Return on Equity (ROE)
-6.60%
TTM Avg
-10.82%
3Y Avg
-11.36%
5Y Avg
-7.59%
Market Cap
$444.41M
Return on Equity (ROE)
-160.85%
TTM Avg
-225.75%
3Y Avg
-186.61%
5Y Avg
-129.85%
Market Cap
$448.31M
Return on Equity (ROE)
-97.92%
TTM Avg
-59.21%
3Y Avg
-49.84%
5Y Avg
-46.25%
Market Cap
$425.52M
Return on Equity (ROE)
-9.23%
TTM Avg
-76.14%
3Y Avg
-50.80%
5Y Avg
-36.67%
Market Cap
$425.13M
Return on Equity (ROE)
-1721.80%
TTM Avg
-73.40%
3Y Avg
-45.77%
5Y Avg
-18.46%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tectonic Therapeutic, Inc. (TECX) | $436.92M | -38.32% | -30.49% | -34.69% | -45.63% |
| Assembly Biosciences, Inc. (ASMB)vs › | $438.56M | -0.01% | -61.70% | -96.25% | -81.28% |
| Capricor Therapeutics, Inc. (CAPR)vs › | $442.54M | -52.56% | -31.09% | -101.75% | -86.54% |
| Editas Medicine, Inc. (EDIT)vs › | $430.46M | -70.24% | -381.56% | -217.03% | -155.40% |
| NeoGenomics, Inc. (NEO)vs › | $429.36M | -6.60% | -10.82% | -11.36% | -7.59% |
| NeuroPace, Inc. (NPCE)vs › | $444.41M | -160.85% | -225.75% | -186.61% | -129.85% |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $448.31M | -97.92% | -59.21% | -49.84% | -46.25% |
| Tilray Brands, Inc. (TLRY)vs › | $425.52M | -9.23% | -76.14% | -50.80% | -36.67% |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $425.13M | -1721.80% | -73.40% | -45.77% | -18.46% |
| Ovid Therapeutics Inc. (OVID)vs › | $448.87M | -16.43% | -26.04% | -38.16% | -45.00% |
ROE
-38.3%
ROA
-36.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -38.32% |
| 2026-03-31 | -36.23% |
| 2025-12-31 | -29.50% |
| 2025-09-30 | -25.16% |
| 2025-06-30 | -23.25% |
| 2025-03-31 | -19.49% |
| 2024-12-31 | -41.19% |
| 2024-09-30 | -35.57% |
| 2024-06-30 | -27.54% |
| 2024-03-31 | -49.08% |
| 2023-06-30 | -56.27% |
| 2023-03-31 | -162.78% |
| 2022-09-30 | -111.21% |
| 2022-06-30 | -100.32% |
| 2022-03-31 | -85.26% |
| 2021-09-30 | -61.49% |
| 2021-06-30 | -55.75% |
| 2021-03-31 | -51.79% |
| 2020-12-31 | -47.07% |
| 2020-09-30 | -54.96% |
| 2020-06-30 | -39.46% |
| 2020-03-31 | -31.90% |
| 2019-12-31 | -39.23% |
| 2019-09-30 | -32.08% |
| 2019-06-30 | -65.60% |
| 2019-03-31 | -51.71% |
| 2018-12-31 | -37.94% |
